Loading organizations...
§ Private Profile · One Broadway, 14th Floor, Cambridge, Massachusetts
Teal Omics is a company.
Key people at Teal Omics.
Teal Omics was founded in 2021 by Alex Boches (Co-Founder, President).
Teal Omics is a biotechnology company that develops artificial intelligence and machine learning tools to study and measure biological aging. The firm focuses on creating advanced analytical capabilities and novel aging biomarkers, which offer powerful biological insights into age-related diseases and the underlying mechanisms of aging. Its technical approach centers on leveraging sophisticated algorithms to quantify and understand various aspects of the aging process.
The company was founded in 2022, stemming from pioneering research at Stanford University. Co-founder Tony Wyss-Coray, a distinguished figure in the field, was instrumental in the development of a machine learning method capable of estimating the aging rate of individual organs. This fundamental insight into systemic and organ-specific aging provided the impetus for establishing Teal Omics.
Teal Omics' work primarily serves entities within the biomedical and pharmaceutical sectors, enabling a deeper understanding of aging for therapeutic development. The company’s long-term vision is to defeat diseases by advancing the science of aging, ultimately striving to translate biological insights into interventions that improve human health and longevity.
Key people at Teal Omics.
Teal Omics was founded in 2021 by Alex Boches (Co-Founder, President).
Teal Omics is a biotech startup founded in 2021 in Cambridge, Massachusetts, developing advanced multi-omics platforms to map human biology at unprecedented depth, with a focus on aging biomarkers, organ-specific aging clocks, and precision medicine.[1][2][3][4] It builds tools like Teal Rise, which transforms complex proteomics and genomics data into actionable insights for biomarker discovery, tracking organ resilience, and causal inference, serving researchers, pharma companies, and clinicians tackling age-related diseases and therapies.[4] The company solves key challenges in biology by providing proteomics-led organ aging clocks across 11+ organ systems, built on datasets from 100K+ proteomics samples and 50K+ matched genotypes, accelerating drug development and early intervention.[4] Backed by investors like IKJ Capital and FORM Life Ventures, Teal has shown early validation in 45K+ UK Biobank participants, positioning it for growth in the booming longevity sector.[1][4]
Teal Omics emerged from the lab of Dr. Tony Wyss-Coray at Stanford University, where foundational research on proteogenomic mapping and organ aging clocks yielded breakthrough results published on the cover of *Nature* in December 2023.[4] The company's technology stems from this work, validated across over 45,000 UK Biobank participants and responsive to interventions like treatments or lifestyle factors.[4] Founded in 2021, it relocated or maintains ties to Cambridge, MA, with early team members like Alex Boches, an entrepreneur driving enterprise innovation in biotech.[1][2] Pivotal early traction came from assembling one of the world's largest datasets—100K+ proteomics profiles across 20+ cohorts—enabling novel biomarkers for aging and disease risk, which attracted seed funding from longevity-focused VCs like IKJ Capital and FORM Life Ventures.[1][4]
Teal Omics stands out in multi-omics through:
Teal Omics rides the longevity biotech wave, capitalizing on surging demand for precision medicine amid aging populations and multi-omics advancements.[1][2][4] Timing is ideal post-2023 *Nature* publication, as AI-driven biology and large biobanks like UK Biobank enable scalable insights, with market forces like $10B+ annual proteomics investments favoring data-rich players.[4] It influences the ecosystem by democratizing organ-level biology for pharma (e.g., faster trials) and researchers, bridging Stanford academia to commercial therapies, and setting standards for intervention-responsive biomarkers in a field where 90% of age-related drugs fail early detection.[3][4]
Teal Omics is poised to lead proteomics-led precision medicine, with next steps likely including platform expansions, pharma partnerships, and Series A funding to scale Teal Rise globally.[1][4] Trends like AI-multiomics integration and regulatory pushes for aging endpoints (e.g., FDA longevity pilots) will propel growth, potentially evolving its influence from biomarker pioneer to full therapy developer. As multi-omics unlocks biological insight, Teal's deep mapping could redefine aging interventions, delivering the powerful tools it promised from day one.[4]
